BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 7072727)

  • 21. Safe Medical Devices Act: management guidance for hospital compliance with the new FDA requirements.
    Alder HC
    Hosp Technol Ser; 1993 Oct; 12(11):1-27. PubMed ID: 10129209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA reform in Congress: FDA's concerns. Food and Drug Administration.
    James JS
    AIDS Treat News; 1996 Apr; (no 245):5-7. PubMed ID: 11363624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Over-the-counter drug products containing colloidal silver ingredients or silver salts. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule.
    Fed Regist; 1999 Aug; 64(158):44653-8. PubMed ID: 10558603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An interview with FDA commissioner Hayes.
    Small WE
    Am Pharm; 1981 Oct; NS21(10):27-36. PubMed ID: 6803557
    [No Abstract]   [Full Text] [Related]  

  • 25. Content and format of labeling for human prescription drugs; pregnancy labeling; public hearing--FDA. Notice of public hearing; request for comments.
    Fed Regist; 1997 Jul; 62(147):41061-3. PubMed ID: 10169832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fees for certifying insulin drugs--FDA. Interim rule; opportunity for public comment.
    Fed Regist; 1991 Oct; 56(193):50248-9. PubMed ID: 10114373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA perspectives on health claims for food labels.
    Rowlands JC; Hoadley JE
    Toxicology; 2006 Apr; 221(1):35-43. PubMed ID: 16480811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA'S food ingredient approval process: Safety assurance based on scientific assessment.
    Rulis AM; Levitt JA
    Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Promoting public health and protecting consumers in a global economy: an overview of HHS/FDA's international activities.
    Kelly DP; Bachorik LL
    Food Drug Law J; 2005; 60(3):339-46. PubMed ID: 16304741
    [No Abstract]   [Full Text] [Related]  

  • 30. Amendment to examination and investigation sample requirements--FDA. Direct final rule.
    Fed Regist; 1998 Sep; 63(186):51297-9. PubMed ID: 10185810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiperspirant drug products for over-the-counter human use; final monograph. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(110):34273-93. PubMed ID: 12795305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The growing debate over FDA reform. Food and Drug Administration.
    Link D
    GMHC Treat Issues; 1996 Jan; 10(1):1-5. PubMed ID: 11363372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug labeling; sodium labeling for over-the-counter drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Nov; 69(228):69278-80. PubMed ID: 15570675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 35. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDA reform: activists' proposals. Food and Drug Administration.
    James JS
    AIDS Treat News; 1995 Aug; (no 228):6-8. PubMed ID: 11362628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
    Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Introducing new contraceptives.
    Segal SJ; Coutinho E
    Draper Fund Rep; 1986 Dec; (15):27-32. PubMed ID: 12341234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA policy on unapproved drug products: past, present, and future.
    Chhabra R; Kremzner ME; Kiliany BJ
    Ann Pharmacother; 2005; 39(7-8):1260-4. PubMed ID: 15956239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Philip Morris' FDA gambit: good for public health?
    Givel M
    J Public Health Policy; 2005 Dec; 26(4):450-68. PubMed ID: 16392744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.